DDD Partners LLC Has $3.93 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

DDD Partners LLC increased its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 2.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 800,922 shares of the company’s stock after purchasing an additional 17,225 shares during the period. DDD Partners LLC owned approximately 0.55% of Adaptive Biotechnologies worth $3,925,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its position in Adaptive Biotechnologies by 2.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 53,701 shares of the company’s stock worth $382,000 after acquiring an additional 1,225 shares during the last quarter. Legal & General Group Plc grew its position in Adaptive Biotechnologies by 1.7% during the 4th quarter. Legal & General Group Plc now owns 94,308 shares of the company’s stock worth $721,000 after acquiring an additional 1,569 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Adaptive Biotechnologies by 23.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,432 shares of the company’s stock worth $57,000 after buying an additional 1,587 shares during the period. UBS Group AG lifted its holdings in Adaptive Biotechnologies by 6.8% during the 3rd quarter. UBS Group AG now owns 27,005 shares of the company’s stock worth $193,000 after buying an additional 1,725 shares during the period. Finally, Vident Investment Advisory LLC lifted its holdings in Adaptive Biotechnologies by 14.1% during the 4th quarter. Vident Investment Advisory LLC now owns 15,159 shares of the company’s stock worth $116,000 after buying an additional 1,871 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, insider Kyle Piskel sold 7,727 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $3.43, for a total transaction of $26,503.61. Following the completion of the sale, the insider now directly owns 123,318 shares of the company’s stock, valued at approximately $422,980.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, President Julie Rubinstein sold 39,070 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $3.47, for a total value of $135,572.90. Following the completion of the transaction, the president now directly owns 472,754 shares of the company’s stock, valued at $1,640,456.38. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Kyle Piskel sold 7,727 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total value of $26,503.61. Following the completion of the transaction, the insider now directly owns 123,318 shares of the company’s stock, valued at $422,980.74. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,307 shares of company stock valued at $428,090. Corporate insiders own 5.20% of the company’s stock.

Adaptive Biotechnologies Stock Performance

ADPT stock opened at $2.89 on Thursday. The stock’s 50 day simple moving average is $3.74 and its 200 day simple moving average is $4.39. Adaptive Biotechnologies Co. has a fifty-two week low of $2.61 and a fifty-two week high of $9.08. The company has a market cap of $419.31 million, a P/E ratio of -1.85 and a beta of 1.27.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. The business had revenue of $45.78 million for the quarter, compared to the consensus estimate of $50.15 million. Adaptive Biotechnologies had a negative return on equity of 53.65% and a negative net margin of 132.29%. Equities analysts predict that Adaptive Biotechnologies Co. will post -1.31 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on ADPT. The Goldman Sachs Group cut their target price on Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, February 16th. JPMorgan Chase & Co. dropped their price objective on Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating on the stock in a research note on Thursday, February 15th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.